R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Associate Director - GxP Electronic Systems Quality Assurance

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
Full-timeRedwood City, CA, USAHybrid

About the Job

Requirements

  • A bachelor's degree in Life Sciences, Engineering, Computer Science, Information Systems, or a related discipline and 10 or more years of experience in pharmaceutical, biotechnology, or another regulated life sciences environment.
  • Demonstrated experience in Computerized System Validation (CSV), Computer Software Assurance (CSA), and Quality oversight of GxP computerized systems across the system lifecycle.
  • Strong knowledge of applicable regulations and industry guidance, including 21 CFR Part 11, EU Annex 11, GAMP 5, data integrity principles, and global GxP requirements.
  • Experience providing Quality oversight for enterprise GxP platforms, cloud/SaaS applications, system implementations, upgrades, integrations, and data migrations.
  • Demonstrated ability to lead cross-functional initiatives and effectively partner with Quality, IT, system owners, business process owners, and technology vendors.

Responsibilities

  • Provide Global Quality oversight for GxP computerized systems, ensuring compliant implementation and lifecycle management across GMP, GCP, GLP, GVP, and GDP environments.
  • Provide strategic quality leadership for Computerized System Validation (CSV) and Computer Software Assurance (CSA), including risk-based validation approaches, system changes, upgrades, integrations, data migrations, and periodic reviews.
  • Lead, develop, and mentor the team, providing strategic direction and ensuring effective execution of CSV/CSA, Quality platform oversight, AI implementation, and digital compliance priorities.
  • Own Quality oversight and governance of enterprise Quality digital platforms, including Veeva Vault and other GxP quality applications, ensuring platforms remain validated, inspection-ready, scalable, and fit for intended use.
  • Establish and maintain digital Quality governance, including system ownership, change/release management, vendor oversight, access controls, audit trails, electronic records/signatures, and data integrity requirements.
  • Lead Quality governance and implementation of Artificial Intelligence (AI) and emerging technologies within GxP processes, including generative AI, AI agents, machine learning, and intelligent automation.
  • Develop risk-based frameworks for AI qualification, validation/assurance, change management, and ongoing monitoring in alignment with evolving regulatory expectations.
  • Partner with Quality, Information Science, Clinical teams, Regulatory, Pharmacovigilance, PDM, and other business functions to develop and execute the digital Quality roadmap and identify opportunities for compliant automation and process optimization.
  • Serve as the Digital Systems QA subject matter expert for regulatory inspections and audits, maintaining inspection readiness and monitoring evolving FDA, EMA, PMDA, GAMP 5, 21 CFR Part 11, EU Annex 11, data integrity, CSA, and AI-related regulatory expectations.

Desired Qualifications

  • An advanced degree in Life Sciences, Engineering, Computer Science, Information Systems, or a related discipline.
  • Experience with Veeva Vault Quality Suite or comparable enterprise Quality Management platforms.
  • Experience implementing or providing Quality governance for AI, generative AI, machine learning, AI agents, intelligent automation, or other emerging technologies within a regulated environment.
  • Knowledge of evolving FDA, EMA, PMDA, and global regulatory expectations for AI, digital technologies, cloud platforms, and risk-based computer software assurance.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs